BMS/AbbVie's combo falls short in untreated multiple myeloma...

Adding Bristol-Myers Squibb/AbbVie's Empliciti to Revlimid, developed by BMS' recently acquired Celgene unit, does not improve survival in untreated multiple myeloma, a study has shown.

Sanofi gets first OK for isatuximab for myeloma, challenging...

Janssen's Darzalex approved in EU for newly-diagnosed multip...

Janssen’s Darzalex (daratumumab) has been approved in Europe as a combination therapy in newly-diagnosed patients with multiple myeloma.

Life with multiple myeloma

Multiple myeloma patient Bob Munro (pictured below) explains what it's like to live with the rare blood cancer and how his diagnosis led him on the journey of a lifetime – cycling from

GSK files multiple myeloma drug with FDA after phase 2 succe...

GSK has filed for FDA approval of its potential first-in-class multiple myeloma drug belantamab mafodotin for relapsed/refractory multiple myeloma on the basis of a set of strong results fr

J&J gets okay for a third first-line Darzalex combo in US